NASDAQ$LGVN
Longeveron Inc-A · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Longeveron reported Q1 2026 revenue of $0.4M with a net loss of $4.7M.
For the quarter ended March 31, 2026, Longeveron reported total revenues of $0.40 million (clinical trial, contract manufacturing) versus $0.38 million a year ago. Gross profit was $0.26 million. Net loss was $4.7 million versus $5.0 million in Q1 2025.
- Revenue $0.4M from trial and manufacturing services.
- Net loss $4.7M, modestly improved YoY.
- Investigational candidates still in development.
- Gross profit $0.26M on low revenue base.
Headline financials
Revenue & EPS history
Longeveron · Revenue · Quarterly
$398K
Revenue by segment
Longeveron · $150K total across 1 segment · Q4 2023
- Clinical Trial Revenue$150K—100.0%
Forward guidance
No product revenue guidance; dependent on clinical progress and partnerships.
Tailwinds
- Slight revenue growth year over year.
- Lower net loss versus prior year.
Headwinds
- Pre-commercial model with ongoing R&D spend.
- Limited revenue scale.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2026
-5.1%
Avg return
Earnings day
-5.7%
Avg return
5 days after
+22.2%
Avg return
30 days after
35%
7 / 20 earnings
Positive
+10.0%
Q1 2022
Best reaction
-35.7%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.7% | -11.0% | +4.3% | |
| Q4 2025 | -4.7% | -0.7% | +6.1% | |
| Q3 2025 | -4.3% | -7.3% | -23.1% | |
| Q1 2025 | -10.1% | -9.4% | -17.4% | |
| Q4 2024 | -9.2% | -5.3% | +2.0% | |
| Q3 2024 | -2.3% | -8.8% | -14.3% | |
| Q2 2024 | -7.5% | -11.3% | -21.8% | |
| Q1 2024 | +3.1% | -1.5% | +106.9% | |
| Q4 2023 | +0.7% | +0.0% | -39.8% | |
| Q3 2023 | -6.7% | -0.5% | +17.6% | |
| Q2 2023 | -6.5% | -12.0% | -25.8% | |
| Q1 2023 | -6.1% | -11.9% | -0.9% | |
| Q4 2022 | -15.5% | -17.5% | -25.0% | |
| Q3 2022 | +5.1% | +2.6% | -14.1% | |
| Q2 2022 | +3.9% | +1.3% | -14.5% | |
| Q1 2022 | +10.0% | +16.2% | -0.7% | |
| Q4 2021 | -14.4% | -7.1% | +37.8% | |
| Q3 2021 | -4.9% | -15.6% | +461.6% | |
| Q2 2021 | -35.7% | -32.9% | -31.1% | |
| Q1 2021 | +1.7% | +17.9% | +35.8% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro